<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="564">
  <stage>Registered</stage>
  <submitdate>12/09/2005</submitdate>
  <approvaldate>16/09/2005</approvaldate>
  <actrnumber>ACTRN12605000416695</actrnumber>
  <trial_identification>
    <studytitle>IBCSG 24-02 / BIG 2-02: Suppression of Ovarian Function Trial</studytitle>
    <scientifictitle>IBCSG 24-02 / BIG 2-02: Suppression of Ovarian Function Trial. A phase III trial evaluating the role of ovarian function suppression and the role of Exemestane as adjuvant therapies for premenopausal women with endocrine responsive breast cancer.</scientifictitle>
    <utrn />
    <trialacronym>SOFT</trialacronym>
    <secondaryid>ClinicalTrials.gov:  NCT00066690</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Adjuvant Breast Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>IBCSG 24-02 / BIG 2-02 (SOFT) is being conducted internationally by the International Breast Cancer Study Group (IBCSG). The study is coordinated in Australia and New Zealand by Breast Cancer Trials (formerly the Australia and New Zealand Breast Cancer Trials Group). This study will evaluate the worth of ovarian function suppression (achieved by long-term use of GnRH analogue (triptorelin), surgical oophorectomy or ovarian irradiation) plus tamoxifen compared with tamoxifen alone for premenopausal women with steroid hormone receptor positive early invasive breast cancer who either receive no adjuvant chemotherapy or remain premenopausal following adjuvant and/or neoadjuvant chemotherapy. In addition, the worth of exemestane will be evaluated for this premenopausal patient population by comparing ovarian function suppression plus exemestane with tamoxifen alone and by comparing ovarian function suppression plus exemestane with ovarian function suppression plus tamoxifen. IBCSG 24-02 / BIG 2-02 (SOFT) is an international, multicentre, randomised phase III clinical trial of 3000 premenopausal women who have had histologically or cytologically confirmed, receptor-positive primary breast cancer. Women will be randomised in a 3-arm design to receive one of the following: a. Tamoxifen b. Ovarian Function Suppression + tamoxifen c. Ovarian Function Suppression + exemestane Patients are stratified according to institution, prior chemotherapy, number of positive nodes and the intended initial method of ovarian function suppression if assigned by randomization. All treatment will be for 5 years. </interventions>
    <comparator>Tamoxifen 20mg, orally, daily for five years</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Disease-free survival</outcome>
      <timepoint>Disease free survival will be assessed annually starting when 200 events have been observed in the three treatment arms for a total of 5 analyses over 6.9 years.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To compare overall survival.</outcome>
      <timepoint>Overall survival will be assessed every 3 months in Year 1, every 6 months during years 2-6 and yearly thereafter until death</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Systemic disease-free survival</outcome>
      <timepoint>Systemic disease survival will be assessed every 3 months in Year 1, every 6 months during years 2-6 and yearly thereafter until death</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life</outcome>
      <timepoint>Quality of Life will be assessed at baseline, and at months 6, 12, 18, 24, 36, 48, 60 and 72</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Sites of first treatment failure</outcome>
      <timepoint>Sites of first treatment failure will be assessed every 3 months in Year 1, every 6 months during years 2-6 and yearly thereafter until death</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Late side effects of early menopause</outcome>
      <timepoint>Late side effects of early menopause will be assessed every 3 months in Year 1, every 6 months during years 2-6 and yearly thereafter until death</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of second (non-breast) malignancies </outcome>
      <timepoint>Incidence of second (non-breast) malignancies will be assessed every 3 months in Year 1, every 6 months during years 2-6 and yearly thereafter until time of onset or until death</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Causes of death without cancer event between the treatment arms.</outcome>
      <timepoint>Causes of death without cancer event between the treatment arms will be assessed every 3 months in Year 1, every 6 months during years 2-6 and yearly thereafter intil time of onset or until death</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Pre-menopausal women with histologically proven, hormone receptor positive, completely resected breast cancer which is confined to the breast and axillary nodes without metastases; axillary node dissection or a negative axillary sentinel node biopsy; geographically accessible for follow up; written informed consent provided.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Post-menopausal women; distant metastatic disease; locally advanced inoperable breast cancer; supraclavicular node involvement; enlarged internal mammary nodes; bilateral invasive breast cancer; positive final margins; clinically detectable residual axillary disease; history of prior ipsilateral or contralateral invasive breast cancer; previous or concomitant malignancy; other non-malignant systemic diseases that would prevent prolonged follow-up; bilateral oophorectomy or ovarian irradiation or are planning oophorectomy within 5 years of entry; pregnant or lactating at randomization; desire a pregnancy within 5 years or plan to use additional hormone therapy during next 5 years (including hormonal contraception); neoadjuvant or adjuvant endocrine therapy for more than 6 months after breast cancer diagnosis; tamoxifen or other SERM or HRT within 1 year prior to breast cancer diagnosis; patients who have received GnRH analogues as part of their breast cancer treatment prior to randomisation.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>The ANZ BCTG Statistical Centre at the NHMRC Clinical Trials Centre, University of Sydney will provide a central randomisation service by fax for all Australian and New Zealand institutions. At the time of study entry all participants will be allocated a treatment code via a web-based randomization system and study drug will be supplied in accordance with the treatment code.</concealment>
    <sequence>Computer generated stratified blocks.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>22/11/2004</anticipatedstartdate>
    <actualstartdate>17/03/2005</actualstartdate>
    <anticipatedenddate />
    <actualenddate>18/02/2010</actualenddate>
    <samplesize>3000</samplesize>
    <actualsamplesize>3066</actualsamplesize>
    <currentsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>31/12/2023</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia,Outside</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,TAS,WA,VIC</recruitmentstate>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>Breast Cancer Trials</primarysponsorname>
    <primarysponsoraddress>PO Box 283
The Junction NSW 2291</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Breast Cancer Trials</fundingname>
      <fundingaddress>PO Box 283
The Junction NSW 2291</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>International Breast Cancer Study Group</sponsorname>
      <sponsoraddress>IBCSG Coordinating Center
Effingerstrasse 40
3008 Bern
SWITZERLAND</sponsoraddress>
      <sponsorcountry>Switzerland</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Phase 3

This trial evaluates the role of suppressing ovarian function, and also the role of the drug exemestane as preventative therapies for premenopausal women with breast cancer that responds to hormones. 

Who is it for?
You can join this study if you are a woman with early breast cancer that responds to hormones and you are still premenopausal even after treatment (with surgery or chemotherapy). 

Trial details 
Chemotherapy, hormone tablets, and turning off the ovaries all reduce the risk of breast cancer coming back in young women with early breast cancer that responds to hormone therapy.  However it is unclear whether all 3 are necessary or what the best way to combine them is. This study will determine if turning off the ovaries for 5 years helps young women with early breast cancer

Participants will be randomly assigned to receive Tamoxifen alone (standard treatment for this group of patients), ovarian function suppression with Tamoxifen, or ovarian function suppression with Exemestane (a drug designed to reduce the amount of oestrogen in the body, so as to reduce cancer growth).  Patients assigned to ovarian function suppression as part of their treatment will be able to choose the method of treatment (either by tablet, radiotherapy or surgery).</summary>
    <trialwebsite>www.breastcancertrials.org.au</trialwebsite>
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes>Breast Cancer Trials formerly known as the Australia &amp; New Zealand Breast Cancer Trials Group.</publicnotes>
    <ethicscommitee>
      <ethicname>The Alfred Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Austin Health</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Ballarat Oncology and Haematology Services</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Box Hill Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Concord Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Frankston Hospital (Rosebud Hospital  Satellite Site)</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Geelong Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Liverpool Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Macarthur Cancer Therapy Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Maroondah Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Mater Hospital, Sydney</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St Vincents and Mercy Private</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Monash Medical Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Mount Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Newcastle Mater Misericordiae Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Peter MacCallum Cancer Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate>1/11/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Prince of Wales Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Riverina Cancer Care Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Brisbane and Womens Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Hobart Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal North Shore Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Prince Alfred Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St George Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St John of God, Bunbury</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St John of God, Subiaco</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St Vincents Hospital, Sydney</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Prue Francis</name>
      <address>Medical Oncology Department
Peter MacCallum Cancer Centre
Locked Bag 1
A'Beckett Street
MELBOURNE VIC 8006 </address>
      <phone>+61 (03) 8559-7902</phone>
      <fax />
      <email>Prue.Francis@petermac.org</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Corinna Beckmore</name>
      <address>BCT
PO Box 283
The Junction NSW 2291</address>
      <phone>+61 2 4925 5235</phone>
      <fax>+61 4925 3068</fax>
      <email>enquiries@bctrials.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Prue Francis</name>
      <address>Medical Oncology Department 
Peter MacCallum Cancer Centre
Locked Bag 1
A'Beckett Street
MELBOURNE      VIC   8006</address>
      <phone>+61 (03) 8559-7902</phone>
      <fax />
      <email>Prue.Francis@petermac.org</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>